Home » News and Views » Destiny Pharma #DEST – Developing Novel Medicines that Prevent Serious Infections. Alan Green talks to CEO Neil Clark

Destiny Pharma #DEST – Developing Novel Medicines that Prevent Serious Infections. Alan Green talks to CEO Neil Clark

  • Two exciting¬†late stage clinical assets – XF-73 and NTCD-M3
  • China Medical Systems – new XF-73 programme in China
  • NTCD-M3 Phase 3 studies
  • Spore COV – JV progress and Innovate funding
  • Cash runway and upcoming value inflection points

Leave a comment

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.